Cover Image
市場調查報告書

角膜移植片排斥反應 : 開發平台分析

Corneal Graft Rejection - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 253680
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
角膜移植片排斥反應 : 開發平台分析 Corneal Graft Rejection - Pipeline Review, H1 2016
出版日期: 2016年03月22日 內容資訊: 英文 44 Pages
簡介

角膜移植是將健康的角膜組織移植代替受損的角膜組織,但有時人體的免疫系統會對新的組織產生排斥反應。排斥反應有出現在移植後數個月,也有經過數年才發病的。主要的症狀有眼睛充血、疼痛、發炎、畏光、視力低落等。主要治療法有類固醇劑和免疫抑制劑等。

本報告提供全球各國治療角膜移植後排斥反應所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

角膜移植片排斥反應概要

治療藥的開發

  • 角膜移植片排斥反應開發中產品:概要
  • 角膜移植片排斥反應開發中產品:比較分析

各企業開發中的角膜移植片排斥反應治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

角膜移植片排斥反應治療藥:開發中的產品一覽(各企業)

角膜移植片排斥反應治療藥的開發企業

  • Circadian Technologies Limited
  • Oxford BioMedica Plc

角膜移植片排斥反應:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • Cyndacel-M
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • EncorStat
  • GB-301
  • 角膜移植片排斥反應基質細胞療法
  • VGX-100

角膜移植片排斥反應治療藥:開發中產品的最新趨勢

角膜移植片排斥反應治療藥:暫停中的計劃

角膜移植片排斥反應相關的產品開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7786IDB

Summary

Global Markets Direct's, 'Corneal Graft Rejection - Pipeline Review, H1 2016', provides an overview of the Corneal Graft Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Corneal Graft Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Corneal Graft Rejection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Corneal Graft Rejection
  • The report reviews pipeline therapeutics for Corneal Graft Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Corneal Graft Rejection therapeutics and enlists all their major and minor projects
  • The report assesses Corneal Graft Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Corneal Graft Rejection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Corneal Graft Rejection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Corneal Graft Rejection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Corneal Graft Rejection Overview
  • Therapeutics Development
    • Pipeline Products for Corneal Graft Rejection - Overview
  • Corneal Graft Rejection - Therapeutics under Development by Companies
  • Corneal Graft Rejection - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Corneal Graft Rejection - Products under Development by Companies
  • Corneal Graft Rejection - Companies Involved in Therapeutics Development
    • Circadian Technologies Limited
    • Gene Signal International SA
    • Oxford BioMedica Plc
    • Santen Pharmaceutical Co., Ltd.
  • Corneal Graft Rejection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aganirsen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GB-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OXB-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stromal Cell Therapy for Corneal Graft Rejection - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VGX-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Corneal Graft Rejection - Recent Pipeline Updates
  • Corneal Graft Rejection - Dormant Projects
  • Corneal Graft Rejection - Product Development Milestones
    • Featured News & Press Releases
      • Jan 30, 2012: VGX-100 Identified As Potential New Therapy For Improving Corneal Graft Survival
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Corneal Graft Rejection, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Corneal Graft Rejection - Pipeline by Circadian Technologies Limited, H1 2016
  • Corneal Graft Rejection - Pipeline by Gene Signal International SA, H1 2016
  • Corneal Graft Rejection - Pipeline by Oxford BioMedica Plc, H1 2016
  • Corneal Graft Rejection - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Corneal Graft Rejection Therapeutics - Recent Pipeline Updates, H1 2016
  • Corneal Graft Rejection - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Corneal Graft Rejection, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top